gabexate and Biliary Tract Diseases studies

Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

Biliary Tract Diseases: Diseases in any part of the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.

Research Excerpts

Excerpt	Relevance	Reference
"A continuous 13-h infusion of gabexate starting 30-90 min before endoscopic cholangiopancreatography (ERCP) can reduce postprocedural pancreatitis, the onset of which is generally observed within the first 6 h after ERCP."	9.10	Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. ( Cavallini, G; Costamagna, G; Curioni, S; Dragonetti, C; Frulloni, L; Innocenti, P; Macarri, G; Mariani, A; Masci, E; Testoni, PA; Tittobello, A; Uomo, G; Zambelli, S, 2003)
"A continuous 13-h infusion of gabexate starting 30-90 min before endoscopic cholangiopancreatography (ERCP) can reduce postprocedural pancreatitis, the onset of which is generally observed within the first 6 h after ERCP."	5.10	Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. ( Cavallini, G; Costamagna, G; Curioni, S; Dragonetti, C; Frulloni, L; Innocenti, P; Macarri, G; Mariani, A; Masci, E; Testoni, PA; Tittobello, A; Uomo, G; Zambelli, S, 2003)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

gabexate and Biliary Tract Diseases

Research Excerpts

Research

Studies (1)

Authors

Trials

Authors	Studies
Masci, E	1
Cavallini, G	1
Mariani, A	1
Frulloni, L	1
Testoni, PA	1
Curioni, S	1
Tittobello, A	1
Uomo, G	1
Costamagna, G	1
Zambelli, S	1
Macarri, G	1
Innocenti, P	1
Dragonetti, C	1